Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA - PubMed (original) (raw)
Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA
I Parr et al. Br J Cancer. 1973 May.
Free PMC article
Abstract
Double stranded RNA (dsRNA) whether isolated from a fungal virus or prepared synthetically (i.e., Poly I Poly C) and endotoxin were found to exert very similar effects on syngeneic murine lymphomata and fibrosarcomata. They cause complete regressions of some established subcutaneous (s.c.) or intradermal (i.d.) tumours but not of intraperitoneal (i.p.) tumours when administered either systemically or directly into the tumour. To achieve this effect the tumours must be fully established and the best results were obtained when treatment was started 7 days after transplant. If treatment is started within the first 3 days following the transplantation of the tumour then only a slight inhibition of growth rate was observed. These agents can also act prophylactically and protect mice against a subsequent challenge but only if this is given i.p. and not if given s.c. or i.d. The prophylactic action is explained by the action of dsRNA and endotoxin on peritoneal macrophages which cause them to become cytotoxic to tumour cells (i.e., to become activated).The therapeutic effect of systemically administered endotoxin and dsRNA on established tumours is not the result of a direct action on the tumour cells themselves but is a complex process requiring the co-operation of several host factors. Haemorrhagic necrosis involving coagulation is essential (i.e., heparinization reduces the regression of tumours) but is not itself sufficient. Immunosuppression by whole body irradiation or by antilymphocyte serum also interferes with the antitumour action of dsRNA and endotoxin in spite of the fact that haemorrhagic necrosis still occurs. Also, the magnitude of the antitumour action correlated in a series of different tumours with their antigenicity. The observed tumour regressions are probably brought about by (1) vascular damage in the tumour which permits immune defence mechanisms of the host to gain access to the tumour and (2) activation of macrophages present within the tumour. The relative contribution of these two mechanisms may depend on the nature of the tumour and the route of administration of the active agents.Dibenyline, which protects against the lethal action of endotoxin by preventing the action of the catecholamines on the α-adrenergic receptors, makes it possible to increase the effectiveness of endotoxin in tumours by allowing a large dose to be given. Lipid A, a derivative of endotoxin which does not contain polysaccharide, has similar antitumour action to dsRNA and endotoxin. Some common features of the chemical structure of lipid A and dsRNA are discussed.
Similar articles
- Multiple mechanisms involved in the antitumour action of endotoxin and double stranded RNA.
Alexander P. Alexander P. Johns Hopkins Med J Suppl. 1974;3:321-32. Johns Hopkins Med J Suppl. 1974. PMID: 4421487 No abstract available. - Failure to relate the anti-tumour action of cyclophosphamide with the immunogenicity of two murine fibrosarcomas.
Evans R. Evans R. Int J Cancer. 1978 May 15;21(5):611-6. doi: 10.1002/ijc.2910210511. Int J Cancer. 1978. PMID: 659026 - Haemorrhagic tumour necrosis following endotoxin administration. I. Communication: morphological investigation on endotoxin-induced necrosis of the methylcholanthrene (Meth A) tumour in the mouse.
Freudenberg N, Joh K, Westphal O, Mittermayer C, Freudenberg MA, Galanos C. Freudenberg N, et al. Virchows Arch A Pathol Anat Histopathol. 1984;403(4):377-89. doi: 10.1007/BF00737287. Virchows Arch A Pathol Anat Histopathol. 1984. PMID: 6429940 - The response to chemotherapy of a variety of human tumour xenografts.
Steel GG, Courtenay VD, Peckham MJ. Steel GG, et al. Br J Cancer. 1983 Jan;47(1):1-13. doi: 10.1038/bjc.1983.1. Br J Cancer. 1983. PMID: 6336942 Free PMC article. Review. - Possible relationships between in vivo antitumour activity and toxicity of tumour necrosis factor-alpha.
Palladino MA Jr, Patton JS, Figari IS, Shalaby MR. Palladino MA Jr, et al. Ciba Found Symp. 1987;131:21-38. doi: 10.1002/9780470513521.ch3. Ciba Found Symp. 1987. PMID: 3330012 Review.
Cited by
- Translatable Drug-Loaded Iron Oxide Nanophore Sensitizes Murine Melanoma Tumors to Monoclonal Antibody Immunotherapy.
Stater EP, Morcos G, Isaac E, Ogirala A, Hsu HT, Longo VA, Grimm J. Stater EP, et al. ACS Nano. 2023 Apr 11;17(7):6178-6192. doi: 10.1021/acsnano.2c05800. Epub 2023 Mar 27. ACS Nano. 2023. PMID: 36971591 Free PMC article. - Manufacturing-dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development.
Steeghs N, Hansen AR, Hanna GJ, Garralda E, Park H, Strauss J, Adam M, Campbell G, Carver J, Easton R, Mays K, Skrdla P, Struemper H, Washburn ML, Matheny C, Piha-Paul SA. Steeghs N, et al. Clin Transl Sci. 2022 Nov;15(11):2625-2639. doi: 10.1111/cts.13387. Epub 2022 Sep 12. Clin Transl Sci. 2022. PMID: 36097345 Free PMC article. Clinical Trial. - Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid A treatment.
Martin A, Seignez C, Racoeur C, Isambert N, Mabrouk N, Scagliarini A, Reveneau S, Arnould L, Bettaieb A, Jeannin JF, Paul C. Martin A, et al. Oncotarget. 2018 Jun 19;9(47):28364-28378. doi: 10.18632/oncotarget.25342. eCollection 2018 Jun 19. Oncotarget. 2018. PMID: 29983866 Free PMC article. - Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.
Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, Ragot K, Lizard G, Jeannin JF, Bardou M. Isambert N, et al. BMC Cancer. 2013 Apr 2;13:172. doi: 10.1186/1471-2407-13-172. BMC Cancer. 2013. PMID: 23547558 Free PMC article. Clinical Trial. - A model for cancer-suppressive inflammation.
Haabeth OA, Bogen B, Corthay A. Haabeth OA, et al. Oncoimmunology. 2012 Oct 1;1(7):1146-1155. doi: 10.4161/onci.21542. Oncoimmunology. 2012. PMID: 23170261 Free PMC article.
References
- Eur J Biochem. 1969 Jan;7(3):370-9 - PubMed
- Angew Chem Int Ed Engl. 1970 Sep;9(9):649-63 - PubMed
- Eur J Biochem. 1971 Mar 1;19(1):143-52 - PubMed
- Transplantation. 1972 Oct;14(4):468-73 - PubMed
- J Exp Med. 1953 Jun;97(6):871-88 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources